Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NINJA : The NINJA Clinical Trial: Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation

Male or<br/>FemaleGender Male or
Female

Closed (no longer recruiting)Status Closed (no longer recruiting)

Radiotherapy<br/>TrialTypeRadiotherapy
Trial

UnknownPhase Unknown

18+Age Over 18

Prostate<br/>CancersCancer LocationProstate
Cancers

Radiotherapy | Urinary systemProstate

Trial Overview Read MoreRead more

This trial is comparing the effectiveness of two schedules of radiotherapy for the treatment of patients with prostate cancer.
 

This trial is treating patients with prostate cancer.

This is a radiation therapy.

You may be able to join this trial if:

  • Your cancer has not spread to other parts of the body.

You may be excluded from this trial if:

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

The NINJA Clinical Trial: Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation

Cooperative Group

Trans Tasman Radiation Oncology Group (TROG)

Commercial Sponsor

Mundipharma Research Limited

Other Non-Commercial Sponsor

Australian and New Zealand Urogenital and Prostate cancer trials group (ANZUP)

Summary

Patients eligible to participate in this study will receive radiation therapy, which will be delivered by one of two schedules. The first schedule will involve 40 Grays (Gy) of radiation delivered in five fractions 1-3 times per week. The second schedule will involve 20Gy in 2 fractions delivered once per week, followed by a two week break and 36Gy in 12 fractions, delivered 4-5 times per week. All patients will receive injections of androgen deprivation therapy for 6 months, commencing 3-4 months prior to radiation.

Not Recruiting Hospitals Read MoreRead more

Closed

Peter MacCallum Cancer Centre
Moorabbin
Moorabbin Research
moorabbin.research@petermac.org
03 9928 8994

Peter MacCallum Cancer Centre, Radiation Oncology
Parkville
Smitha Sithara
Smitha.sithara@petermac.org
03 8559 8771

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next